Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05726383 · ClinicalTrials.gov registry record · Phase 2
Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma
A Phase 2 study of Osteogenic Sarcoma Recurrent, sponsored by Hackensack Meridian Health.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 2
- Study locations
NCT05726383 is a Phase 2 study of Osteogenic Sarcoma Recurrent that is actively recruiting participants, run by Hackensack Meridian Health. The registered enrollment target is 32 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT05726383, a Phase 2 study of Osteogenic Sarcoma Recurrent, is actively recruiting participants, sponsored by Hackensack Meridian Health.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 2
- Study locations
Study Summary
This will be a phase II, single arm study of osteosarcoma patients with fully resected pulmonary metastases. The MTD corresponds to the dosage recommendations of the manufacturer of Iscador® P which is licensed in Sweden, New Zealand, South Korea, Germany and Switzerland for the treatment of solid tumors and precancerous lesions. The study population includes patients with relapse of osteosarcoma in the lung following surgical resection of all gross disease (2nd or greater CR). Following completion of final thoracotomy, they will be treated with Iscador® P at concentrations up to the MTD with surveillance imaging via CT scan to monitor for relapsed disease.
Conditions Studied
Interventions
- DRUG Iscador*P
Study Locations (2)
New Jersey
- Hackensack University Medical Center - Hackensack
Texas
- M.D. Anderson Children's Cancer Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2024-05-14 |
| Est. Completion | 2027-05-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05726383
The ClinicalTrials.gov registry entry for NCT05726383 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteogenic Sarcoma Recurrent appearing as the primary indexed condition, and to 1 intervention - of which Iscador*P is the first listed.
NCT05726383 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, Texas.
Frequently Asked Questions
What is clinical trial NCT05726383 about?
NCT05726383 is a clinical study titled "Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma". This will be a phase II, single arm study of osteosarcoma patients with fully resected pulmonary metastases. The MTD corresponds to the dosage recommendations of the manufacturer of Iscador® P which is licensed in Sweden, New Zealand, South Korea, Germany and Switzerland for the treatment of solid t...
What is the current status of trial NCT05726383?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2024-05-14. Estimated completion is 2027-05-11.
What conditions does trial NCT05726383 study?
This clinical trial studies the following conditions: Osteogenic Sarcoma Recurrent.
What interventions are being tested in trial NCT05726383?
The interventions under investigation include: Iscador*P (DRUG).
Who is sponsoring clinical trial NCT05726383?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05726383 being conducted?
This trial has 2 study locations across New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.